Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMS Pay For Off-Label Use Of Avastin In Wet Age-Related Macular Degeneration May Discourage Use

This article was originally published in The Pink Sheet Daily

Executive Summary

Rate based on Avastin's cancer indication puts ophthalmologists in the position of choosing whether to take a loss to administer it to Medicare beneficiaries or get full reimbursement for the more expensive, FDA-approved Lucentis.

You may also be interested in...



CMS Reverses Avastin Reimbursement Limits For Macular Degeneration In Physicians' Office

Change comes amid criticism that new reimbursement rate would discourage use of the cheaper off-label alternative to FDA-approved Lucentis.

CMS Reverses Avastin Reimbursement Limits For Macular Degeneration In Physicians' Office

Change comes amid criticism that new reimbursement rate would discourage use of the cheaper off-label alternative to FDA-approved Lucentis.

Deals Of The Week: Novartis/Paratek, Genentech/SurModics, GSK/Walvax ...

Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.

Related Content

Topics

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel